Skip to main content

Morphine-Ketamine Combo Effective for Trauma Analgesia in Field

NEW YORK (Reuters Health) Jan 25 - Out in the field, giving ketamine after an initial dose of morphine is more effective than continuing morphine in adults with significant trauma injuries, according to Australian researchers.
"Furthermore, adverse events were uncommon in this nonphysician EMS setting," they reported online January 16 in Annals of Emergency Medicine.
Dr. Paul Andrew Jennings of Monash University in Melbourne, Victoria, and colleagues note that while morphine is commonly used for acute traumatic pain, it often causes respiratory depression and nausea.
Ketamine is appealing for use in the out-of-hospital setting, they explain, because of its analgesic and dissociative properties and its opioid-sparing effect. In addition, they write, "it is purported to allow patients to maintain their pharyngeal reflexes and maintain their own airway, even when fully dissociated."
To investigate further, the team conducted a randomized open-label trial involving 135 adults with significant out-of-hospital trauma pain and verbal pain scores greater than 5 after receiving 5 mg IV morphine. They were then assigned to receive a 10- or 20-mg bolus of ketamine followed by 10 mg every three minutes, or 5 mg of morphine every five minutes, until pain free.
Median baseline pain scores were 7.5 in the ketamine group and 7.0 in the morphine group. Scores were reduced by -5.6 and -3.2 points in the two groups, respectively, the authors report. The difference of 2.4 points in favor of the ketamine protocol exceeded the specified 1.3 points for a minimum clinically important effect.
Furthermore, the ketamine group had a faster reduction in pain than the morphine group, the report indicates.
Adverse effects were minor, although the rate was higher with ketamine (39%) than morphine-only (14%). No adverse event required withdrawal from the study, Dr. Jennings and colleagues note.
Summing up, they conclude, "Supplementing out-of-hospital opioids with low-dose ketamine is an effective strategy to mitigate trauma pain."
They add, "Given the success of intravenous ketamine in the reduction of refractory acute pain, future research should focus on the effectiveness of alternative routes of administration, including intramuscular, intranasal, and topical applications. Furthermore, the utility of various dosing regimens such as continuous or patient-controlled infusion needs to be explored with respect to effectiveness and ease of out-of-hospital maintenance and administration."

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...